Insider buying last 90 days
No open-market insider purchases were filed for CORT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Corcept Therapeutics this week drew attention on multiple fronts following its Q3 2026 report on 3 November. Revenue reached $340.5 million, up 64% year-over-year, with Korlym/authorized generic contributing $249.1 million and newly launched Lifyorli adding $91.4 million. Net income rose to $126.8 million from $19.7 million a year earlier, and cash stood at $662 million. Commentary since has centered on valuation, with CORT trading at 7.9 times trailing revenue versus the S&P 500's 3.3 times, alongside a Moderate Buy consensus rating cited by MarketBeat.com. Separate filings noted insider stock sales by the president of oncology and a former president of Corcept Endocrinology under pre-arranged trading plans.
CORT closed at $75.03, up 3.1% on the day, with its close sitting between the 50-day average of $106.80 and the 200-day average of $75.94. The one-month return stands at -38.1% and the three-month return at -32.9%, while the six-month return is 46.5%. The GekkoIndex reads 73.6, placing the stock in the Buying zone, down 3.7 over five days. Price sits 25.2% below the Gekko Fair Value of $100.33.
The next earnings date falls on 23 February 2027, 105 days out and beyond a typical 20-trading-day holding window; the prior report produced a -1.5% reaction despite beating estimates, with four beats in the last eight quarters. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality for this calendar point shows a 20-trading-day average return of 3% over five years, rising in three of them. Four analysts carry Buy ratings with a consensus target of $141, implying 87.9% consensus upside.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Corcept Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Averages disagree
Close $72.94 sits between the 50-day ($103.70) and 200-day ($76.50) averages, or the averages disagree.
See the chart68.6, Accumulation
Reading 68.6 is in the Accumulation zone.
See the GekkoIndex25.3% below
Price is 25.3% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings−0.4% on average
From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Corcept Therapeutics closed at $72.94 on Nov 13, 2026, −7.0% over the past year, inside a 52-week range of $28.66 to $126.38.
Use the left and right arrow keys to read daily values.
Put CORT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Corcept Therapeutics focuses on treatments for patients dealing with serious hormonal, cancer-related, and mental health conditions, marketing its products within the United States. Its main approved treatment is Korlym, a mifepristone tablet taken once each day, used to address elevated blood sugar linked to excess cortisol in adults facing endogenous Cushing's syndrome, especially those managing type 2 diabetes or impaired glucose tolerance who are not candidates for surgery or have not benefited from it.
Alongside this marketed treatment, Corcept continues research into new therapies. One candidate, relacorilant, is being tested as a standalone option for Cushing's syndrome and also paired with nab-paclitaxel, a combination that has finished Phase II study for ovarian cancer that has spread and is under review for other illnesses tied to elevated cortisol levels. Separate efforts target selective cortisol modulators meant for prostate cancer that resists standard hormone therapy and for weight gain linked to antipsychotic drugs, together with laboratory research into a gene expression assay tied to FKBP5.
Corcept Therapeutics shares trade on the NASDAQ under the ticker CORT.
Corcept Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.6, in the Accumulation zone, down 7.5 points over five sessions.
Down 7.5 points over five sessions, from the Buying zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 26 | −1.8% | +7.8% | ||
| Accumulation (current zone) | 169 | +1.7% | +11.7% | ||
| Neutral | 428 | +1.8% | +4.6% | ||
| Distribution | 75 | −0.3% | +3.9% | ||
| Selling | 4 | Too few readings yet | |||
Average CORT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Corcept Therapeutics trades 25.3% below Gekko Fair Value of $97.61, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Corcept Therapeutics shares are worth, recalculated every trading day.
$97.61
Gekko Fair Value, Nov 14, 2026
25.3% Undervalued
At the end of Aug 2026 the price was 12.9% above the estimate.
No open-market insider purchases were filed for Corcept Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CORT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CORT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Corcept Therapeutics has been buying back its own shares.
From company filings.
Corcept Therapeutics reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 3, 2026 | $1.01 est $0.79 | $340.5M est $336.4M | −1.5% |
| Jul 29, 2026 | $0.36 est −$0.04 | $256.1M est $221.1M | +25.6% |
| Apr 30, 2026 | −$0.30 est −$0.14 | $164.9M est $185.3M | +10.4% |
| Feb 24, 2026 | $0.20 est $0.25 | $202.1M est $254.9M | +2.5% |
| Nov 4, 2025 | $0.16 est $0.18 | $207.6M est $255.3M | +3.3% |
| Jul 31, 2025 | $0.29 est $0.19 | $194.4M est $244.6M | −1.3% |
| May 5, 2025 | $0.17 est $0.14 | $157.2M est $216.7M | −2.8% |
| Feb 26, 2025 | $0.26 est $0.42 | $181.9M est $200.1M | −2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Corcept Therapeutics is $142.60, +95.5% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | H.C. Wainwright | $165 | +126.2% |
| Nov 5 | Canaccord Genuity | $161 | +120.7% |
| Nov 4 | Piper Sandler | $173 | +137.2% |
| Nov 2 | H.C. Wainwright | $165 | +126.2% |
| Oct 26 | Piper Sandler | $165 | +126.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Corcept Therapeutics averaged −0.4% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 3 of 5 |
| Next 10 trading days | +0.1% | 3 of 5 |
| Next 15 trading days | +1.2% | 3 of 5 |
| Next 20 trading days | −0.4% | 2 of 5 |
| Next 30 trading days | −4.7% | 1 of 5 |
For scale, CORT’s typical 20-trading-day move in either direction is about 10.1%.
Corcept Therapeutics’s market cap is $7.98B, with a P/E ratio of 55.4 and revenue of $963.6M over the last twelve months.
Coverage of Corcept Therapeutics this week reads neutral: 1 positive, 3 neutral and 1 negative headlines.
Corcept Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Corcept Therapeutics’s market cap is $7.98B at the Nov 13, 2026 close of $72.94, with 109.4M shares outstanding. The shares trade on a P/E ratio of 55.4.
The consensus analyst 12-month price target for Corcept Therapeutics is $142.60, +95.5% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Corcept Therapeutics is undervalued: the Nov 13, 2026 close of $72.94 is 25.3% below Gekko Fair Value of $97.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Corcept Therapeutics is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $1.12 per share on revenue of $396.6M. Corcept Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.2% on average across the report.
Corcept Therapeutics’s 52-week high is $126.38 and its 52-week low is $28.66; it closed at $72.94 on Nov 13, 2026, −7.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.